Northwestern Mutual Wealth Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.39K	Buy	451 +406	+902%	+$1.57K	﹤0.01%	3688
2025 Q4	$184	Buy	45 +44	+4,400%	+$218	﹤0.01%	3813
2025 Q3	$5	Buy	+1	New	+$5	﹤0.01%	3781
2024 Q4	–	Sell	-5,399	Closed	-$35.6K	–	3845
2024 Q3	$35.6K	Buy	+5,399	New	+$38.7K	﹤0.01%	2277
2022 Q1	–	Sell	-8	Closed	–	–	3359
2021 Q4	$0	Buy	+8	New	+$151	﹤0.01%	3303

Other funds holding RXRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $352M AUM 0.23% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Northwestern Mutual Wealth Management's RXRX Position: Q1 2026 in Review

Northwestern Mutual Wealth Management increased its Recursion Pharmaceuticals (RXRX) stake by 902% in Q1 2026, buying an estimated $1.57K and bringing the position to 451 shares worth $1.39K. The position accounts for ﹤0.01% of the portfolio, ranked #3688.

Northwestern Mutual Wealth Management first reported a position in RXRX in Q4 2021 and has held it in 5 quarters since. The position peaked at $35.6K in Q3 2024. 334 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Northwestern Mutual Wealth Management held 451 shares of Recursion Pharmaceuticals worth $1.39K as of Q1 2026.
Northwestern Mutual Wealth Management bought 406 Recursion Pharmaceuticals shares in Q1 2026, an estimated $1.57K.
Recursion Pharmaceuticals made up ﹤0.01% of Northwestern Mutual Wealth Management's portfolio in Q1 2026, its #3688 holding.
Northwestern Mutual Wealth Management first reported a position in Recursion Pharmaceuticals in Q4 2021 and has held it in 5 quarters since.
Northwestern Mutual Wealth Management's Recursion Pharmaceuticals position peaked at $35.6K in Q3 2024.
334 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Northwestern Mutual Wealth Management's 13F filing for Q1 2026, filed 7 May 2026.